Filings & corporate actions
44 results filed
CSVNext results · Q2 FY27
Expected 7 Nov 2026 – 13 Nov 2026
Estimate: filed 38–44 days after quarter end, last 5 times
Dividend
₹10.00 per share · last 7 Aug 2026
2026
- 14 AugresultsResults · Q1 FY27 · consolidated and standalone+0.1%NSE
- 7 AugdividendDividend · ₹10.00 per share+0.4%
- 9 JulshareholdingShareholding · 30 Jun 2026+0.8%NSE
- 28 MayresultsResults · Q4 FY26 · consolidated and standalone+0.9%NSE
- 15 AprshareholdingShareholding · 31 Mar 2026+3.9%NSE
- 20 FebdividendDividend · ₹43.00 per share+0.3%
- 13 FebresultsResults · Q3 FY26 · consolidated and standalone+1.4%NSE
- 13 JanshareholdingShareholding · 31 Dec 2025-0.1%NSE
Reaction to results · all yearsrose on day 0 in 20 of 45 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 14 Aug 2026 | +0.1% | -0.3% | -3.9% | 1.3× |
| Q4 FY26 | 28 May 2026 | +0.9% | -3.7% | -0.6% | 16.6× |
| Q3 FY26 | 13 Feb 2026 | +1.4% | +1.6% | -1.3% | 0.9× |
| Q2 FY26 | 13 Nov 2025 | -0.1% | -0.4% | -1.7% | 2.6× |
| Q1 FY26 | 12 Aug 2025 | +4.7% | +5.3% | +5.8% | 6.7× |
| Q4 FY25 | 29 May 2025 | -3.7% | -8.2% | -7.3% | 6.5× |
| Q3 FY25 | 7 Feb 2025 | -6.8% | -6.9% | -7.3% | 7.7× |
| Q2 FY25 | 13 Nov 2024 | -0.8% | -1.7% | -2.3% | 1.4× |
| Q1 FY25 | 9 Aug 2024 | -1.4% | -1.1% | +9.0% | 1.0× |
| Q4 FY24 | 29 May 2024 | -6.0% | -7.8% | -5.2% | 6.5× |
| Q3 FY24 | 9 Feb 2024 | -3.4% | +2.7% | -3.2% | 1.3× |
| Q2 FY24 | 7 Nov 2023 | +5.1% | +7.9% | +21.4% | 7.1× |
| Q1 FY24 | 10 Aug 2023 | -7.7% | -7.7% | -12.3% | 3.8× |
| Q4 FY23 | 19 May 2023 | -1.5% | +1.4% | +3.0% | 1.3× |
| Q3 FY23 | 10 Feb 2023 | -0.8% | -0.5% | -6.3% | 2.0× |
| Q2 FY23 | 11 Nov 2022 | -0.9% | -2.8% | -1.8% | 4.0× |
| Q1 FY23 | 5 Aug 2022 | -4.1% | -5.6% | +1.8% | 5.0× |
| Q4 FY22 | 13 May 2022 | 0.0% | +2.8% | +6.5% | 1.5× |
| Q3 FY22 | 4 Feb 2022 | -0.8% | -4.2% | -7.1% | 0.4× |
| Q2 FY22 | 12 Nov 2021 | +1.1% | -5.7% | -2.4% | 2.8× |
| Q1 FY22 | 6 Aug 2021 | +1.2% | +7.0% | +9.1% | 1.8× |
| Q4 FY21 | 25 May 2021 | +1.1% | +8.6% | +7.1% | 1.0× |
| Q3 FY21 | 5 Feb 2021 | -1.4% | -2.0% | -5.4% | 1.2× |
| Q2 FY21 | 6 Nov 2020 | +0.6% | -2.7% | +5.6% | 1.9× |
| Q1 FY21 | 7 Aug 2020 | -0.1% | -3.2% | -5.4% | 1.4× |
| Q4 FY20 | 5 Jun 2020 | -0.8% | -1.0% | -2.5% | 1.7× |
| Q3 FY20 | 7 Feb 2020 | +3.3% | +3.2% | +3.5% | 5.0× |
| Q2 FY20 | 11 Nov 2019 | +4.8% | +5.7% | +5.9% | 4.5× |
| Q1 FY20 | 13 Aug 2019 | +1.6% | -1.0% | +4.4% | 0.6× |
| Q4 FY19 | 27 Jun 2019 | -0.8% | +3.3% | +7.9% | 0.4× |
| Q3 FY19 | 13 Feb 2019 | -1.9% | -0.2% | -6.5% | 7.0× |
| Q2 FY19 | 23 Nov 2018 | -0.9% | -1.8% | -4.3% | 5.0× |
| Q1 FY19 | 24 Aug 2018 | -0.7% | +7.3% | +0.9% | 2.3× |
| Q4 FY18 | 26 Jun 2018 | -0.2% | -3.2% | +3.3% | 0.2× |
| Q3 FY18 | 16 Mar 2018 | -2.2% | -5.4% | -20.9% | 3.1× |
| Q2 FY18 | 11 Nov 2017 | +2.4% | +1.7% | +9.4% | 1.7× |
| Q1 FY18 | 21 Aug 2017 | -3.4% | -2.3% | -3.5% | 0.5× |
| Q4 FY17 | 29 May 2017 | +3.0% | +6.1% | +0.8% | 0.8× |
| Q3 FY17 | 17 Feb 2017 | +1.7% | +7.0% | +8.4% | 1.2× |
| Q2 FY16 | 17 Nov 2016 | +1.5% | +4.6% | -0.9% | 1.0× |
| Q2 FY17 | 17 Nov 2016 | +1.5% | +4.6% | -0.9% | 1.0× |
| Q1 FY17 | 27 Sept 2016 | +2.1% | -7.7% | -9.7% | 0.7× |
| Q1 FY16 | 27 Sept 2016 | +2.1% | -7.7% | -9.7% | 0.7× |
| Q4 FY16 | 28 May 2016 | +2.2% | +9.3% | +10.8% | 1.8× |
| Q3 FY16 | 13 Feb 2016 | -0.4% | -2.9% | +2.8% | 0.7× |
| Average | -0.2% | -0.2% | -0.1% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+10.9%
Profit YoY-22.0%
Interest cost YoY+45.1%
Revenue QoQ+3.8%
Profit QoQ+107.5%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +8.8% | +7.9% | — | — | +10.0% | +10.4% |
| Profit | +3.1% | +23.7% | — | — | +8.0% | +15.1% |
Key data
CSVOpen5,223.50
Day range5,165.00 – 5,292.00
52-week range5,051.00 – 5,933.50
From 52w high-10.8%
RSI (14)50.4
ATR (14)124.63
Volume63.7K
Avg volume (20D)1.59L
Rel volume0.40×
Volatility (1Y)21.8%
Turnover₹33.7Cr
SMA 50 / 2005,381.06 / 5,482.55
Delivery percentage
Latest · 6 Oct 202652.4%
20-day avg57.4%
1-year avg54.8%
Percentile (own history)47th
Range10.9–94.2%
Sessions1,731
Over the last 20 sessions ALKEM settled 57.4% of its traded quantity, which is above average for an NSE equity. Its one-year average is 54.8%, so recent sessions are running 2.5 points higher than usual. The latest session ranks higher than 47% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +1.92% | +2.26% | +1.91% | -6.63% | +0.65% | -2.60% |
Valuation
CSVMarket cap₹63,274 Cr
P/E (TTM)28.7
EPS (TTM)184.35
Shares outstanding11.96Cr
Listed23 Dec 2015
Ownership
CSVPromoter49.70%
Promoter Δ QoQ-1.50 pp
Public50.30%
FII10.42%
DII22.63%
Pledged0.00%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 4,001.0 | 3,736.8 | 3,603.3 | 3,740.2 |
| YoY chg | +17.2% | +10.7% | +14.6% | +10.9% |
| Net profit (₹ Cr) | 779.1 | 653.0 | 251.1 | 521.0 |
| YoY chg | +11.0% | +1.9% | -22.1% | -22.0% |
| Net margin | 19.5% | 17.5% | 7.0% | 13.9% |
| EPS | 63.99 | 53.19 | 19.77 | 43.49 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 49.70% · public 50.30%2021-092026-06
- Promoter
- Public and others
- Promoter
- 49.70%
- Public
- 50.30%
- Promoter change
- -1.50 pp
- Filed
- 9 Jul 2026
- FII
- 10.42%
- DII
- 22.63%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 3,440.2 | 3,323.9 | 2,935.8 | 3,031.8 | 3,414.7 | 3,374.3 | 3,143.8 | 3,371.1 | 4,001.0 | 3,736.8 | 3,603.3 | 3,740.2 | |
| Other income | 63.2 | 93.6 | 88.2 | 120.3 | 134.5 | 93.0 | 146.0 | 136.5 | 103.7 | 143.1 | 200.1 | 152.8 | |
| Total income | 3,503.4 | 3,417.5 | 3,024.0 | 3,152.1 | 3,549.2 | 3,467.3 | 3,289.7 | 3,507.6 | 4,104.7 | 3,879.9 | 3,803.4 | 3,892.9 | |
| Total expenses | 2,797.7 | 2,711.3 | 2,644.1 | 2,532.8 | 2,768.9 | 2,736.2 | 2,893.4 | 2,749.6 | 3,208.9 | 3,045.9 | 3,245.6 | 3,120.9 | |
| └ Finance costs | 30.3 | 25.5 | 26.9 | 29.1 | 28.1 | 36.0 | 28.4 | 29.8 | 35.0 | 42.1 | 53.9 | 46.6 | |
| └ Depreciation | 73.9 | 69.6 | 83.4 | 80.5 | 78.9 | 85.3 | 112.5 | 87.7 | 93.6 | 95.0 | 105.8 | 100.2 | |
| Profit before tax | 648.0 | 654.9 | 367.3 | 619.4 | 780.3 | 731.1 | 396.3 | 771.0 | 895.8 | 781.2 | 422.9 | 772.0 | |
| Tax expense | 33.2 | 50.6 | 62.9 | 69.1 | 78.3 | 90.3 | 73.3 | 102.7 | 116.2 | 127.7 | 171.2 | 250.5 | |
| Net profit | 614.9 | 604.3 | 304.5 | 550.2 | 702.0 | 640.8 | 322.4 | 667.9 | 779.1 | 653.0 | 251.1 | 521.0 | |
| EPS | 51.90 | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 | 25.57 | 55.56 | 63.99 | 53.19 | 19.77 | 43.49 | |
| Net margin | 17.87% | 18.18% | 10.37% | 18.15% | 20.56% | 18.99% | 10.25% | 19.81% | 19.47% | 17.48% | 6.97% | 13.93% | |
| PBT margin | 18.84% | 19.70% | 12.51% | 20.43% | 22.85% | 21.67% | 12.61% | 22.87% | 22.39% | 20.91% | 11.74% | 20.64% | |
| Tax rate | 5.12% | 7.73% | 17.11% | 11.16% | 10.04% | 12.35% | 18.50% | 13.32% | 12.97% | 16.34% | 40.48% | 32.45% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 14 Aug 2026.
ALKEM at a glance
- ALKEM closed at ₹5,292 on 6 Oct 2026, +1.92% on the day, -2.6% over one year, 10.8% below its 52-week high of ₹5,933.5.
- Delivery was 52.4% of traded quantity on 6 Oct 2026, the 47th percentile of its own 1,731 sessions with a reading (20-session average 57.4%, 1-year average 54.8%).
- Market capitalisation is ₹63,274 crore at a trailing P/E of 28.7 (trailing EPS ₹184.35).
- Q1 FY27 results (consolidated, filed 14 Aug 2026): revenue ₹3,740 crore (+10.9% year on year), net profit ₹521 crore (-22.0%); the price moved +0.1% on the first session after.
- Promoters held 49.70% at 30 Jun 2026, down 1.50 percentage points on the previous filing.
- Q2 FY27 results are expected between 7 Nov 2026 and 13 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE540L01014
SeriesEQ
Listed23 Dec 2015
History from23 Dec 2015
Sessions2,668
Turnover rank#343
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE